cell-free DNA
The firm continues to pursue new applications for its multiomics machine learning technology, with recent data exploring immunotherapy response prediction.
The company is positioning the blood-based test as an alternative to invasive chorionic villus sampling, the current standard in Denmark.
Scottish Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials.Â
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial
The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.
NephroSant Raises $16M in Series A Funding Round
The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.